Clinical trial
The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes
NCT02694575 is registered in ClinicalTrials.gov with University of Leicester as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes
- Lead sponsor
- University of Leicester
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 1, 2015
- Completion date
- August 31, 2018
- Enrollment
- 241 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.